domingo, 19 de mayo de 2013

Building the evidence base for decision making in ... [Genet Med. 2012] - PubMed - NCBI

Building the evidence base for decision making in ... [Genet Med. 2012] - PubMed - NCBI

Genet Med. 2012 Jul;14(7):633-42.

Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research.


Center for Health Research, Kaiser Permanente Northwest, Portland, OR, USA.


The clinical utility is uncertain for many cancer genomic applications. Comparative effectiveness research (CER) can provide evidence to clarify this uncertainty. The aim of this study was to identify approaches to help stakeholders make evidence-based decisions and to describe potential challenges and opportunities in using CER to produce evidence-based guidance. We identified general CER approaches for genomic applications through literature review, the authors' experiences, and lessons learned from a recent, seven-site CER initiative in cancer genomic medicine. Case studies illustrate the use of CER approaches. Evidence generation and synthesis approaches used in CER include comparative observational and randomized trials, patient-reported outcomes, decision modeling, and economic analysis. Significant challenges to conducting CER in cancer genomics include the rapid pace of innovation, lack of regulation, and variable definitions and evidence thresholds for clinical and personal utility. Opportunities to capitalize on CER methods in cancer genomics include improvements in the conduct of evidence synthesis, stakeholder engagement, increasing the number of comparative studies, and developing approaches to inform clinical guidelines and research prioritization. CER offers a variety of methodological approaches that can address stakeholders' needs and help ensure an effective translation of genomic discoveries.

[PubMed - indexed for MEDLINE]
Free PMC Article

No hay comentarios:

Publicar un comentario